Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)UnknownNCT05763992
What this trial is testing

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

Who this might be right for
Breast CancerTriple Negative Breast CancerDietary Exposure+1 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 145
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Ended earlyNCT05714553
What this trial is testing

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Who this might be right for
Advanced CancerAdvanced Solid TumorNeoplasm Malignant+14 more
NuCana plc 19
Early research (Phase 1)Study completedNCT03012230
What this trial is testing

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Who this might be right for
Metastatic Malignant Neoplasm in the BoneStage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Mayo Clinic 12
Testing effectiveness (Phase 2)WithdrawnNCT06710197
What this trial is testing

IL-1 Inhibition in Early TNBC

Who this might be right for
Early Stage Triple Negative ER Low Breast Cancer
University Health Network, Toronto
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06202313
What this trial is testing

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shengjing Hospital 128
Testing effectiveness (Phase 2)Study completedNCT05520723
What this trial is testing

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Who this might be right for
Triple Negative Breast CancerBreast CancerAdvanced HR+/HER2- Breast Cancer
MedSIR 50
Testing effectiveness (Phase 2)UnknownNCT06078670
What this trial is testing

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Fujian Cancer Hospital 96
Early research (Phase 1)Ended earlyNCT04234113
What this trial is testing

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Who this might be right for
Thyroid CancerRenal Cell CarcinomaNon Small Cell Lung Cancer+16 more
SOTIO Biotech AG 115
Testing effectiveness (Phase 2)Looking for participantsNCT06367088
What this trial is testing

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple-negative Breast CancerCadonilimab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 27
Testing effectiveness (Phase 2)UnknownNCT04129996
What this trial is testing

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Early research (Phase 1)Ended earlyNCT03199040
What this trial is testing

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Who this might be right for
Triple Negative Breast CancerTriple Negative Breast NeoplasmsTNBC - Triple-Negative Breast Cancer+1 more
Washington University School of Medicine 18
Not applicableUnknownNCT04059003
What this trial is testing

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Who this might be right for
Breast Neoplasms
Shengjing Hospital 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT05460273
What this trial is testing

Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Who this might be right for
Carcinoma, Non-Small-Cell LungTriple Negative Breast Cancer
AstraZeneca 119
Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Early research (Phase 1)Study completedNCT02890069
What this trial is testing

PDR001 in Combination With LCL161, Everolimus or Panobinostat

Who this might be right for
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Novartis Pharmaceuticals 298
Testing effectiveness (Phase 2)Study completedNCT01575522
What this trial is testing

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Looking for participantsNCT06880029
What this trial is testing

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. 20
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Next Page